Treatment options for Lambert–Eaton myasthenic syndrome

Bibliography

• Titulaer MJ, Lang B, Verschuuren JJGM. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol 2011;10:1098-107
   PubMed Web of Science ®Google Scholar
• Titulaer MJ, Klooster R, Potman M, et al. SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival. J Clin Oncol 2009;27:4260-7
   PubMed Web of Science ®Google Scholar
• Titulaer MJ, Maddison P, Sont JK, et al. Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS. J Clin Oncol 2011;29:902-8
   PubMed Web of Science ®Google Scholar
• Wirtz PW, Willcox N, van der Slik AR, et al. HLA and smoking in prediction and prognosis of small cell lung cancer in autoimmune Lambert-Eaton myasthenic syndrome. J Neuroimmunol 2005;159:230-7
   PubMed Web of Science ®Google Scholar
• Gilhus NE. Lambert-Eaton myasthenic syndrome; pathogenesis, diagnosis, and therapy. Autoimmune Dis 2011;2011:973808
   PubMedGoogle Scholar
• O'Neill JH, Murray NM, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain 1988;111:577-96
   PubMed Web of Science ®Google Scholar
• Pellkofer HL, Armbruster L, Linke R, et al. Managing non-paraneoplastic Lambert-Eaton myasthenic syndrome: clinical characteristics in 25 German patients. J Neuroimmunol 2009;217:90-4
   PubMedGoogle Scholar
• Titulaer MJ, Wirtz PW, Kuks JB, et al. The Lambert-Eaton myasthenic syndrome 1988-2008: a clinical picture in 97 patients. J Neuroimmunol 2008;201-202:153-8
   PubMedGoogle Scholar
• Wirtz PW, Sotodeh M, Nijnuis M, et al. Difference in distribution of muscle weakness between myasthenia gravis and the Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 2002;73:766-8
   PubMed Web of Science ®Google Scholar
• Oh SJ, Kurokawa K, Claussen GC, Ryan HF Jr. Electrophysiological diagnostic criteria of Lambert-Eaton myasthenic syndrome. Muscle Nerve 2005;32:515-20
   PubMed Web of Science ®Google Scholar
• Verschuuren JJGM, Wirtz PW, Titulaer MJ, et al. Available treatment options for the management of Lambert-Eaton myasthenic syndrome. Expert Opin Pharmacother 2006;7:1323-36
   PubMedGoogle Scholar
• Lennon VA, Kryzer TJ, Griesmann GE, et al. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med 1995;332:1467-74
   PubMed Web of Science ®Google Scholar
• Motomura M, Lang B, Johnston I, et al. Incidence of serum anti-P/O-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. J Neurol Sci 1997;147:35-42
   PubMed Web of Science ®Google Scholar
• Nakao YK, Motomura M, Fukudome T, et al. Seronegative Lambert-Eaton myasthenic syndrome: study of 110 Japanese patients. Neurology 2002;59:1773-5
   PubMed Web of Science ®Google Scholar
• Oh SJ, Hatanaka Y, Claussen GC, Sher E. Electrophysiological differences in seropositive and seronegative Lambert-Eaton myasthenic syndrome. Muscle Nerve 2007;35:178-83
   PubMed Web of Science ®Google Scholar
• Roberts A, Perera S, Lang B, et al. Paraneoplastic myasthenic syndrome IgG inhibits 45Ca2+ flux in a human small cell carcinoma line. Nature 1985;317:737-9
   PubMed Web of Science ®Google Scholar
• Graus F, Lang B, Pozo-Rosich P, et al. P/Q type calcium-channel antibodies in paraneoplastic cerebellar degeneration with lung cancer. Neurology 2002;59:764-6
   PubMed Web of Science ®Google Scholar
• Martín-García E, Mannara F, Gutiérrez-Cuesta J, et al. Intrathecal injection of P/Q type voltage-gated calcium channel antibodies from paraneoplastic cerebellar degeneration cause ataxia in mice. J Neuroimmunol 2013;261:53-9
   PubMed Web of Science ®Google Scholar
• Titulaer MJ, Wirtz PW, Willems LNA, et al. Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome. J Clin Oncol 2008;26:4276-81
   PubMed Web of Science ®Google Scholar
• Titulaer MJ, Soffietti R, Dalmau J, et al. Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol 2011;18:19-e3
   PubMed Web of Science ®Google Scholar
• Graus F, Vincent A, Pozo-Rosich P, et al. Anti-glial nuclear antibody: marker of lung cancer-related paraneoplastic neurological syndromes. J Neuroimmunol 2005;165:166-71
   PubMedGoogle Scholar
• Sabater L, Titulaer M, Saiz A, et al. SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology 2008;70:924-8
   PubMed Web of Science ®Google Scholar
• Lipka AF, Verschuuren JJGM, Titulaer MJ. SOX1 antibodies in Lambert-Eaton myasthenic syndrome and screening for small cell lung carcinoma. Ann NY Acad Sci 2012;1275:70-7
   PubMedGoogle Scholar
• Wirtz PW, Smallegange TM, Wintzen AR, Verschuuren JJ. Differences in clinical features between the Lambert-Eaton myasthenic syndrome with and without cancer: an analysis of 227 published cases. Clin Neurol Neurosurg 2002;104:359-63
   PubMed Web of Science ®Google Scholar
• Rose NR, Bona C. Defining criteria for autoimmune diseases (Witebsky's postulates revisited). Immunol Today 1993;14:426-30
   PubMedGoogle Scholar
• Lecky BR. Transient neonatal Lambert-Eaton syndrome. J Neurol Neurosurg Psychiatry 2006;77:1094
   PubMedGoogle Scholar
• Reuner U, Kamin G, Ramantani G, et al. Transient neonatal Lambert-Eaton syndrome. J Neurol 2008;255:1827-8
   PubMedGoogle Scholar
• Lang B, Newsom-Davis J, Wray D, et al. Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome. Lancet (London, England) 1981;2:224-6
   PubMed Web of Science ®Google Scholar
• Lambert EH. Defects of neuromuscular transmission in syndromes other than myasthenia gravis. Ann NY Acad Sci 1966;135:367-84
   PubMed Web of Science ®Google Scholar
• Oh SJ, Kim DS, Head TC, Claussen GC. Low-dose guanidine and pyridostigmine: relatively safe and effective long-term symptomatic therapy in Lambert-Eaton myasthenic syndrome. Muscle Nerve 1997;20:1146-52
   PubMed Web of Science ®Google Scholar
• Lemeignan M, Millart H, Lamiable D, et al. Evaluation of 4-aminopyridine and 3,4-diaminopyridine penetrability into cerebrospinal fluid in anesthetized rats. Brain Res 1984;304:166-9
   PubMed Web of Science ®Google Scholar
• Molgó J, Lundh H, Thesleff S. Potency of 3,4-diaminopyridine and 4-aminopyridine on mammalian neuromuscular transmission and the effect of pH changes. Eur J Pharmacol 1980;61:25-34
   PubMed Web of Science ®Google Scholar
• McEvoy KM, Windebank AJ, Daube JR, Low PA. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N Engl J Med 1989;321:1567-71
   PubMed Web of Science ®Google Scholar
• Oh SJ, Claussen GG, Hatanaka Y, Morgan MB. 3,4-Diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS. Muscle Nerve 2009;40:795-800
   PubMed Web of Science ®Google Scholar
• Sanders DB, Massey JM, Sanders LL, Edwards LJ. A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome. Neurology 2000;54:603-7
   PubMed Web of Science ®Google Scholar
• Wirtz PW, Verschuuren JJ, Van Dijk JG, et al. Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study. Clin Pharmacol Ther 2009;86:44-8
   PubMed Web of Science ®Google Scholar
• Keogh M, Sedehizadeh S, Maddison P. Treatment for Lambert-Eaton myasthenic syndrome. Cochrane Database Syst Rev 2011;CD003279
   Google Scholar
• Wirtz PW, Titulaer MJ, Van Gerven JMA, Verschuuren JJ. 3,4-diaminopyridine for the treatment of Lambert-Eaton myasthenic syndrome. Expert Rev Clin Immunol 2010;6:867-74
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. SUMMARY OF PRODUCT CHARACTERISTICS Firdapse. 2013
   Google Scholar
• Quartel A, Turbeville S, Lounsbury D. Current therapy for Lambert-Eaton myasthenic syndrome: development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatment. Curr Med Res Opin 2010;26(6):1363-75
   PubMed Web of Science ®Google Scholar
• Green DM, Jones AC, Brain KR. Content variability of active drug substance in compounded oral 3,4-diaminopyridine products. J Clin Pharm Ther 2012;37:53-7
   PubMed Web of Science ®Google Scholar
• Nicholl DJ, Hilton-Jones D, Palace J, et al. Open letter to prime minister David Cameron and health secretary Andrew Lansley. BMJ 2010;341:c6466
   PubMedGoogle Scholar
• Tim RW, Massey JM, Sanders DB. Lambert-Eaton myasthenic syndrome: electrodiagnostic findings and response to treatment. Neurology 2000;54:2176-8
   PubMed Web of Science ®Google Scholar
• Lundh H, Nilsson O, Rosén I. Treatment of Lambert-Eaton syndrome: 3,4-diaminopyridine and pyridostigmine. Neurology 1984;34:1324-30
   PubMed Web of Science ®Google Scholar
• Maggi L, Mantegazza R. Treatment of myasthenia gravis: focus on pyridostigmine. Clin Drug Investig 2011;31:691-701
   PubMed Web of Science ®Google Scholar
• Van Sonderen A, Wirtz PW, Verschuuren JJGM, Titulaer MJ. Paraneoplastic syndromes of the neuromuscular junction: therapeutic options in myasthenia gravis, lambert-eaton myasthenic syndrome, and neuromyotonia. Curr Treat Options Neurol 2013;15:224-39
   PubMedGoogle Scholar
• Tim RW, Massey JM, Sanders DB. Lambert-Eaton myasthenic syndrome (LEMS). Clinical and electrodiagnostic features and response to therapy in 59 patients. Ann NY Acad Sci 1998;841:823-6
   PubMed Web of Science ®Google Scholar
• Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology 1998;50:1778-83
   PubMed Web of Science ®Google Scholar
• Newsom-Davis J, Murray NMF. Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome. Neurology 1984;34:480-5
   PubMed Web of Science ®Google Scholar
• Maddison P, Lang B, Mills K, Newsom-Davis J. Long term outcome in Lambert-Eaton myasthenic syndrome without lung cancer. J Neurol Neurosurg Psychiatry 2001;70:212-17
   PubMed Web of Science ®Google Scholar
• Bain PG, Motomura M, Newsom-Davis J, et al. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology 1996;47:678-83
   PubMed Web of Science ®Google Scholar
• Gajdos P, Chevret S, Clair B, et al. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group. Ann Neurol 1997;41:789-96
   PubMed Web of Science ®Google Scholar
• Rønager J, Ravnborg M, Hermansen I, Vorstrup S. Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis. Artif Organs 2001;25:967-73
   PubMed Web of Science ®Google Scholar
• Barth D, Nabavi Nouri M, Ng E, et al. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology 2011;76:2017-23
   PubMed Web of Science ®Google Scholar
• Maddison P, McConville J, Furragia ME, et al. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 2011;82:671-3
   PubMed Web of Science ®Google Scholar
• Pellkofer HL, Voltz R, Kuempfel T. Favorable response to rituximab in a patient with anti-VGCC-positive Lambert-Eaton myasthenic syndrome and cerebellar dysfunction. Muscle Nerve 2009;40:305-8
   PubMed Web of Science ®Google Scholar
• Clamon GH, Evans WK, Shepherd FA, Humphrey JG. Myasthenic syndrome and small cell cancer of the lung. Variable response to antineoplastic therapy. Arch Intern Med 1984;144:999-1000
   PubMedGoogle Scholar
• Chalk CH, Murray NM, Newsom-Davis J, et al. Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma. Neurology 1990;40:1552-6
   PubMed Web of Science ®Google Scholar
• Cho S, Meriney SD. The effects of presynaptic calcium channel modulation by roscovitine on transmitter release at the adult frog neuromuscular junction. Eur J Neurosci 2006;23:3200-8
   PubMedGoogle Scholar
• Tarr TB, Valdomir G, Liang M, et al. New calcium channel agonists as potential therapeutics in Lambert-Eaton myasthenic syndrome and other neuromuscular diseases. Ann NY Acad Sci 2012;1275:85-91
   PubMedGoogle Scholar
• Tarr TB, Malick Q, Liang M, et al. Evaluation of a novel calcium channel agonist for therapeutic potential in lambert-eaton myasthenic syndrome. J Neurosci 2013;33:10559-67
   PubMed Web of Science ®Google Scholar